Navigation Links
Taiho Pharmaceutical ansöker om godkännande att tillverka och sälja det nya antitumörpreparatet TAS-102
Date:2/26/2013

harmaceutical anser att TAS-102 kommer att vara ett viktigt tillskott för cancerpatienter och kommer att fortsätta sitt utvecklingsarbete för att vidga dess användning.

Om TAS-102
TAS-102 är ett antitumörpreparat som består av en kombination av trifluorotymidin (FTD), en nukleosid som införlivas i DNA och stör olika genetiska funktioner som krävs för att cancerceller ska kunna föröka sig, samt tipiracil hydrochloride (TPI), en hämmare av tymidin-fosforylas (som bryter ner FTD) vilket upprätthåller en effektiv blodkoncentration av FTD. TAS-102 administreras två gånger om dagen för att uppnå en total dagsdos på 70mg/kvadratmeter i fem dagar, följt av två dagars vila. Detta repeteras sedan en andra gång. Sedan följer en 14 dagar lång viloperiod, vilket ger ett 28-dagars schema för en kur.

Om TAS-102 klinisk fas-II studie
172 patienter från 20 vårdinrättningar i Japan deltog i fas-II studien som genomfördes under perioden augusti 2009 till april 2010. Målgruppen för studien var ett område där det för närvarande inte finns någon allmänt etablerad behandlingsterapi i Japan – närmare bestämt patienter som är refraktära mot standard cytostatikabehandlingen för metastaserad kolorektal cancer och som redan har fått minst två behandlingsregimer innehållande fluoropyrimidin, irinotekan och oxaliplatin. Patienterna valdes slumpmässigt ut för att få TAS-102 (114 fall) eller placebo (58 fall). Det primära effektmåttet var total överlevnad.

Om den globala kliniska fas-III studien (RECOURSE)


Den globala kliniska fas-III studien (RECOURSE) är en randomiserad, dubbelblind jämförande studie av TAS-102 ge
'/>"/>

SOURCE Taiho Pharmaceutical Co., Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
2. Taiho Pharmaceutical présente une demande dhomologation pour la fabrication et la commercialisation du nouvel agent antitumoral TAS-102
3. Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market Novel Antitumor Agent TAS-102
4. Taiho Pharmaceutical stellt Zulassungsantrag zur Herstellung und Vermarktung des neuartigen Antitumormittels TAS-102
5. Taiho Pharmaceutical presenta una solicitud para fabricar y comercializar el nuevo agente antitumoral TAS-102
6. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
7. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
8. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
9. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
10. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
11. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , 11. Juli 2014  Dilon ... für die molekulare Bildgebung, einschließlich molekularer ... die CE-Zulassung für sein Navigator ® ... Dilon das Produkt jetzt europaweit vertreiben. ... Großteil der europäischen Länder ausgedehnt und ...
(Date:7/10/2014)... , July 10, 2014  RESMED INC. (NYSE: ... quarter and fiscal year ended June 30, 2014 results on ... market close. A press release with ResMed,s results will be ... will host a webcast to discuss operating results and future ... at 1:30 p.m. US Pacific Time and the live webcast ...
(Date:7/10/2014)... 10, 2014   Ventana Medical Systems, Inc.  (Ventana), ... has entered into an agreement with Merck KGaA, Darmstadt, ... Serono in the United States ... Merck KGaA,s biopharmaceutical division on the development and commercialization ... using Ventana,s proprietary diagnostic assays. In alignment with Merck ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... Pharmaceuticals, Inc. (Nasdaq: REGN ) today announced that ... Eastern Time on Monday, December 20, to discuss results of ... retinal vein occlusion (CRVO) and the week 52 follow-up results ... diabetic macular edema (DME).  A press release will be issued ...
... Institute, the Department of Orthopaedic Surgery and the Division ... of Pennsylvania (HUP) have collaborated to form the Penn ... leadership of the Penn Transplant Institute and in collaboration ... organ and tissue donor program which serves the eastern ...
Cached Medicine Technology:Regeneron Schedules December 20, 2010 Teleconference and Webcast to Discuss Results of VEGF Trap-Eye Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and Phase 2 Study in Diabetic Macular Edema (DME) 2Penn Medicine Establishes Hand Transplant Program 2Penn Medicine Establishes Hand Transplant Program 3Penn Medicine Establishes Hand Transplant Program 4Penn Medicine Establishes Hand Transplant Program 5
(Date:7/13/2014)... HealthDay Reporter FRIDAY, July ... sensor for people with diabetes is being developed to measure ... researchers report. Scientists at Brown University in Providence, R.I., ... It uses light, metal and a special enzyme that changes ... diabetics have to prick their fingers to draw blood to ...
(Date:7/13/2014)... 13, 2014 Recently, 2014QuinceaneraDresses.com, the ... unveiled its new range of gorgeous Quinceanera ... the demand for elegant Quinceanera outfits is huge. ... items. All the company’s newly released dresses are ... are all elegant and vivid. , It ...
(Date:7/13/2014)... Texas (PRWEB) July 13, 2014 Epidemiologists ... aGVHD in the 6MM, from 8,062 diagnosed incident cases ... at an Annual Growth Rate (AGR) of 4.35%, during ... the highest number of diagnosed incident cases of aGVHD ... Spain will have the lowest number of diagnosed incident ...
(Date:7/13/2014)... 13, 2014 Wright & Schulte LLC ... been scheduled in July of 2015, in U.S. District ... are in the discovery process in the South ... is presiding over the multidistrict litigation (MDL). The complaints ... of individuals who allege that they took the statin ...
(Date:7/13/2014)... Hope Palliative & Hospice Care announced today that they ... Tamarack Senior Living Community in Palatine, IL. The group, called ... 3rd Wednesdays of every month. This group will begin ... at 55 S. Greeley St. Palatine, IL 60067. It ... cost for the group. , “A grief support group ...
Breaking Medicine News(10 mins):Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community 2
... the Obama Daughters , , WASHINGTON, ... promise: to get a family dog. But concerns about his ... first-dad from making a decision. So, in the meantime, the ... & allergy friendly" toy puppies to the Obama children. , ...
... with imaging exam results may enable a more meticulous ... as a more personal and empathetic approach, according to ... the Radiological Society of North America (RSNA). , ... being and not as an anonymous case study," said ...
... December 2, 2008 As the connection between second-hand ... legislation was passed to reduce such passive smoking, exposures ... January 2009 issue of the American Journal of ... San Francisco, Partners Healthcare, Boston and Columbia University have ...
... POCATELLO, Idaho, Dec. 1 The Ensign Group, Inc.,(Nasdaq: ... & Rehabilitation Center in,Pocatello, Idaho has successfully graduated from ... , (Logo: ... A clinical team led by Laurie House, Director ...
... In the face of one of the most,severe economic ... Board of,Directors has approved an investment of up to ... Plan. Employee pension plans, which are,often heavily invested in ... the nation,s worsening economy. Although conservatively,invested, the Sutter Health ...
... - Disturbing evidence of higher mortality and lower surgery ... and severe leakage may be related to the complexity ... findings of a Mayo Clinic study published this month ... Mitral valve prolapse affects approximately 150 million people worldwide ...
Cached Medicine News:Health News:Asthma and Allergy Foundation Helps New First-Dad Keep His First Promise 2Health News:Patient photos spur radiologist empathy and eye for detail 2Health News:The Ensign Group Successfully Graduates Second Nursing Home From CMS Special Focus Program 2Health News:The Ensign Group Successfully Graduates Second Nursing Home From CMS Special Focus Program 3Health News:Sutter Health Invests Hundreds of Millions in Employee Pension 2Health News:Women with mitral valve prolapse are treated less aggressively than men and may be at high risk 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: